http://new.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Fri, 18 Sep 2026 08:02:38 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://new.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/New+Coverage/B.Riley+Assumes+Anika+Therapeutics+%28ANIK%29+at+Buy/27078375.html <p>B.Riley analyst Madison El-Saadi assumes coverage on Anika Therapeutics (NASDAQ: ANIK) with a Buy rating and a price target of $23.00.</p><p>The analyst comments "We are assuming coverage of ANIK with a Buy rating and raising our price target from $21 to $23. The operational turnaround is now producing the earnings recovery we expect carries its pipeline expansion opportunities, which could have regulatory roadmap clarity in 2H26. Manufacturing upgrades and expense discipline took 2Q26 gross margin to 65% vs 51% (2Q25) and lifted the FY26 adj. EBITDA margin guide to 13%-17%, which we read as a durable base rather than a http://www.streetinsider.com/New+Coverage/B.Riley+Assumes+Anika+Therapeutics+%28ANIK%29+at+Buy/27078375.html Fri, 18 Sep 2026 08:02:38 -0400 ANIK http://www.streetinsider.com/Analyst+Comments/B.Riley+Assumes+Anika+Therapeutics+%28ANIK%29+at+Buy/27078375.html <p>B.Riley analyst Madison El-Saadi assumes coverage on Anika Therapeutics (NASDAQ: ANIK) with a Buy rating and a price target of $23.00.</p><p>The analyst comments "We are assuming coverage of ANIK with a Buy rating and raising our price target from $21 to $23. The operational turnaround is now producing the earnings recovery we expect carries its pipeline expansion opportunities, which could have regulatory roadmap clarity in 2H26. Manufacturing upgrades and expense discipline took 2Q26 gross margin to 65% vs 51% (2Q25) and lifted the FY26 adj. EBITDA margin guide to 13%-17%, which we read as a durable base rather than a http://www.streetinsider.com/Analyst+Comments/B.Riley+Assumes+Anika+Therapeutics+%28ANIK%29+at+Buy/27078375.html Fri, 18 Sep 2026 08:02:38 -0400 ANIK http://www.streetinsider.com/SEC+Filings/Form++144++++++++Anika+Therapeutics%2C+Inc.+++++++++++++++Filed+by%3A+Jellison+William+R/26892308.html si-local-file:///var/storage/secattach/20260807/26892308.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++Anika+Therapeutics%2C+Inc.+++++++++++++++Filed+by%3A+Jellison+William+R/26892308.html Fri, 07 Aug 2026 17:29:00 -0400 ANIK O.00173818 http://www.streetinsider.com/SEC+Filings/Form++144++++++++Anika+Therapeutics%2C+Inc.+++++++++++++++Filed+by%3A+Jellison+William+R/26892308.html si-local-file:///var/storage/secattach/20260807/26892308.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++Anika+Therapeutics%2C+Inc.+++++++++++++++Filed+by%3A+Jellison+William+R/26892308.html Fri, 07 Aug 2026 17:29:00 -0400 ANIK O.00173818 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Anika+Therapeutics%2C+Inc.++For%3A+Aug+03++Filed+by%3A+Fischetti+Gary+P/26875032.html si-local-file:///var/storage/secattach/20260805/26875032.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Anika+Therapeutics%2C+Inc.++For%3A+Aug+03++Filed+by%3A+Fischetti+Gary+P/26875032.html Wed, 05 Aug 2026 16:30:00 -0400 ANIK O.00173818 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Anika+Therapeutics%2C+Inc.++For%3A+Aug+03++Filed+by%3A+Fischetti+Gary+P/26875032.html si-local-file:///var/storage/secattach/20260805/26875032.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Anika+Therapeutics%2C+Inc.++For%3A+Aug+03++Filed+by%3A+Fischetti+Gary+P/26875032.html Wed, 05 Aug 2026 16:30:00 -0400 ANIK O.00173818 http://www.streetinsider.com/Press+Releases/Every+Few+Decades%2C+Aesthetics+Gets+a+New+Category.+One+Preclinical+Company+Thinks+Its+Extra+Cellular+Matrix+Platform+Could+Create+the+Next+One/26862984.html <p><strong>Issued on behalf of Conexeu Sciences Inc. (Nasdaq: CNXU)</strong></p><p>NEW YORK, Aug. 04, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=LrF4u_nq-M6rhKWRIFzyXu_SqHTmlF2LhuF9syLwk8f08DOVrOInZfGu4xhPcOF3GuPEXiVog2j84gNMhsUSgzuPzAL58AtKcaJ1ABt3xUc=" rel="nofollow" target="_blank">American News Group</a> <strong>News Commentary</strong> - The multi-billion-dollar medical aesthetics market is built on a handful of category-defining breakthroughs. The neuromodulator category that Botox^® created. The hyaluronic-acid filler category. The biostimulator category. Each turned a novel way of treating the face into a franchise measured in billions, and the companies that own those categories, from AbbVie (NYSE: ABBV) and Johnson &amp; Johnson (NYSE: JNJ) to InMode (Nasdaq: INMD) and Anika Therapeutics (Nasdaq: ANIK), built enormous businesses around them. Now http://www.streetinsider.com/Press+Releases/Every+Few+Decades%2C+Aesthetics+Gets+a+New+Category.+One+Preclinical+Company+Thinks+Its+Extra+Cellular+Matrix+Platform+Could+Create+the+Next+One/26862984.html Tue, 04 Aug 2026 09:05:00 -0400 ABBV ABBV ANIK ANIK CNXU CNXU INMD INMD JNJ JNJ http://www.streetinsider.com/Press+Releases/Every+Few+Decades%2C+Aesthetics+Gets+a+New+Category.+One+Preclinical+Company+Thinks+Its+Extra+Cellular+Matrix+Platform+Could+Create+the+Next+One/26862984.html <p><strong>Issued on behalf of Conexeu Sciences Inc. (Nasdaq: CNXU)</strong></p><p>NEW YORK, Aug. 04, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=LrF4u_nq-M6rhKWRIFzyXu_SqHTmlF2LhuF9syLwk8f08DOVrOInZfGu4xhPcOF3GuPEXiVog2j84gNMhsUSgzuPzAL58AtKcaJ1ABt3xUc=" rel="nofollow" target="_blank">American News Group</a> <strong>News Commentary</strong> - The multi-billion-dollar medical aesthetics market is built on a handful of category-defining breakthroughs. The neuromodulator category that Botox^® created. The hyaluronic-acid filler category. The biostimulator category. Each turned a novel way of treating the face into a franchise measured in billions, and the companies that own those categories, from AbbVie (NYSE: ABBV) and Johnson &amp; Johnson (NYSE: JNJ) to InMode (Nasdaq: INMD) and Anika Therapeutics (Nasdaq: ANIK), built enormous businesses around them. Now http://www.streetinsider.com/Press+Releases/Every+Few+Decades%2C+Aesthetics+Gets+a+New+Category.+One+Preclinical+Company+Thinks+Its+Extra+Cellular+Matrix+Platform+Could+Create+the+Next+One/26862984.html Tue, 04 Aug 2026 09:05:00 -0400 ABBV ABBV ANIK ANIK CNXU CNXU INMD INMD JNJ JNJ http://www.streetinsider.com/Press+Releases/Every+Few+Decades%2C+Aesthetics+Gets+a+New+Category.+One+Preclinical+Company+Thinks+Its+Extra+Cellular+Matrix+Platform+Could+Create+the+Next+One/26862984.html <p><strong>Issued on behalf of Conexeu Sciences Inc. (Nasdaq: CNXU)</strong></p><p>NEW YORK, Aug. 04, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=LrF4u_nq-M6rhKWRIFzyXu_SqHTmlF2LhuF9syLwk8f08DOVrOInZfGu4xhPcOF3GuPEXiVog2j84gNMhsUSgzuPzAL58AtKcaJ1ABt3xUc=" rel="nofollow" target="_blank">American News Group</a> <strong>News Commentary</strong> - The multi-billion-dollar medical aesthetics market is built on a handful of category-defining breakthroughs. The neuromodulator category that Botox^® created. The hyaluronic-acid filler category. The biostimulator category. Each turned a novel way of treating the face into a franchise measured in billions, and the companies that own those categories, from AbbVie (NYSE: ABBV) and Johnson &amp; Johnson (NYSE: JNJ) to InMode (Nasdaq: INMD) and Anika Therapeutics (Nasdaq: ANIK), built enormous businesses around them. Now http://www.streetinsider.com/Press+Releases/Every+Few+Decades%2C+Aesthetics+Gets+a+New+Category.+One+Preclinical+Company+Thinks+Its+Extra+Cellular+Matrix+Platform+Could+Create+the+Next+One/26862984.html Tue, 04 Aug 2026 09:05:00 -0400 ABBV ABBV ANIK ANIK CNXU CNXU INMD INMD JNJ JNJ http://www.streetinsider.com/Press+Releases/Every+Few+Decades%2C+Aesthetics+Gets+a+New+Category.+One+Preclinical+Company+Thinks+Its+Extra+Cellular+Matrix+Platform+Could+Create+the+Next+One/26862984.html <p><strong>Issued on behalf of Conexeu Sciences Inc. (Nasdaq: CNXU)</strong></p><p>NEW YORK, Aug. 04, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=LrF4u_nq-M6rhKWRIFzyXu_SqHTmlF2LhuF9syLwk8f08DOVrOInZfGu4xhPcOF3GuPEXiVog2j84gNMhsUSgzuPzAL58AtKcaJ1ABt3xUc=" rel="nofollow" target="_blank">American News Group</a> <strong>News Commentary</strong> - The multi-billion-dollar medical aesthetics market is built on a handful of category-defining breakthroughs. The neuromodulator category that Botox^® created. The hyaluronic-acid filler category. The biostimulator category. Each turned a novel way of treating the face into a franchise measured in billions, and the companies that own those categories, from AbbVie (NYSE: ABBV) and Johnson &amp; Johnson (NYSE: JNJ) to InMode (Nasdaq: INMD) and Anika Therapeutics (Nasdaq: ANIK), built enormous businesses around them. Now http://www.streetinsider.com/Press+Releases/Every+Few+Decades%2C+Aesthetics+Gets+a+New+Category.+One+Preclinical+Company+Thinks+Its+Extra+Cellular+Matrix+Platform+Could+Create+the+Next+One/26862984.html Tue, 04 Aug 2026 09:05:00 -0400 ABBV ABBV ANIK ANIK CNXU CNXU INMD INMD JNJ JNJ http://www.streetinsider.com/Press+Releases/Every+Few+Decades%2C+Aesthetics+Gets+a+New+Category.+One+Preclinical+Company+Thinks+Its+Extra+Cellular+Matrix+Platform+Could+Create+the+Next+One/26862984.html <p><strong>Issued on behalf of Conexeu Sciences Inc. (Nasdaq: CNXU)</strong></p><p>NEW YORK, Aug. 04, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=LrF4u_nq-M6rhKWRIFzyXu_SqHTmlF2LhuF9syLwk8f08DOVrOInZfGu4xhPcOF3GuPEXiVog2j84gNMhsUSgzuPzAL58AtKcaJ1ABt3xUc=" rel="nofollow" target="_blank">American News Group</a> <strong>News Commentary</strong> - The multi-billion-dollar medical aesthetics market is built on a handful of category-defining breakthroughs. The neuromodulator category that Botox^® created. The hyaluronic-acid filler category. The biostimulator category. Each turned a novel way of treating the face into a franchise measured in billions, and the companies that own those categories, from AbbVie (NYSE: ABBV) and Johnson &amp; Johnson (NYSE: JNJ) to InMode (Nasdaq: INMD) and Anika Therapeutics (Nasdaq: ANIK), built enormous businesses around them. Now http://www.streetinsider.com/Press+Releases/Every+Few+Decades%2C+Aesthetics+Gets+a+New+Category.+One+Preclinical+Company+Thinks+Its+Extra+Cellular+Matrix+Platform+Could+Create+the+Next+One/26862984.html Tue, 04 Aug 2026 09:05:00 -0400 ABBV ABBV ANIK ANIK CNXU CNXU INMD INMD JNJ JNJ http://www.streetinsider.com/Press+Releases/Every+Few+Decades%2C+Aesthetics+Gets+a+New+Category.+One+Preclinical+Company+Thinks+Its+Extra+Cellular+Matrix+Platform+Could+Create+the+Next+One/26862984.html <p><strong>Issued on behalf of Conexeu Sciences Inc. (Nasdaq: CNXU)</strong></p><p>NEW YORK, Aug. 04, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=LrF4u_nq-M6rhKWRIFzyXu_SqHTmlF2LhuF9syLwk8f08DOVrOInZfGu4xhPcOF3GuPEXiVog2j84gNMhsUSgzuPzAL58AtKcaJ1ABt3xUc=" rel="nofollow" target="_blank">American News Group</a> <strong>News Commentary</strong> - The multi-billion-dollar medical aesthetics market is built on a handful of category-defining breakthroughs. The neuromodulator category that Botox^® created. The hyaluronic-acid filler category. The biostimulator category. Each turned a novel way of treating the face into a franchise measured in billions, and the companies that own those categories, from AbbVie (NYSE: ABBV) and Johnson &amp; Johnson (NYSE: JNJ) to InMode (Nasdaq: INMD) and Anika Therapeutics (Nasdaq: ANIK), built enormous businesses around them. Now http://www.streetinsider.com/Press+Releases/Every+Few+Decades%2C+Aesthetics+Gets+a+New+Category.+One+Preclinical+Company+Thinks+Its+Extra+Cellular+Matrix+Platform+Could+Create+the+Next+One/26862984.html Tue, 04 Aug 2026 09:05:00 -0400 ABBV ABBV ANIK ANIK CNXU CNXU INMD INMD JNJ JNJ http://www.streetinsider.com/Press+Releases/Every+Few+Decades%2C+Aesthetics+Gets+a+New+Category.+One+Preclinical+Company+Thinks+Its+Extra+Cellular+Matrix+Platform+Could+Create+the+Next+One/26862984.html <p><strong>Issued on behalf of Conexeu Sciences Inc. (Nasdaq: CNXU)</strong></p><p>NEW YORK, Aug. 04, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=LrF4u_nq-M6rhKWRIFzyXu_SqHTmlF2LhuF9syLwk8f08DOVrOInZfGu4xhPcOF3GuPEXiVog2j84gNMhsUSgzuPzAL58AtKcaJ1ABt3xUc=" rel="nofollow" target="_blank">American News Group</a> <strong>News Commentary</strong> - The multi-billion-dollar medical aesthetics market is built on a handful of category-defining breakthroughs. The neuromodulator category that Botox^® created. The hyaluronic-acid filler category. The biostimulator category. Each turned a novel way of treating the face into a franchise measured in billions, and the companies that own those categories, from AbbVie (NYSE: ABBV) and Johnson &amp; Johnson (NYSE: JNJ) to InMode (Nasdaq: INMD) and Anika Therapeutics (Nasdaq: ANIK), built enormous businesses around them. Now http://www.streetinsider.com/Press+Releases/Every+Few+Decades%2C+Aesthetics+Gets+a+New+Category.+One+Preclinical+Company+Thinks+Its+Extra+Cellular+Matrix+Platform+Could+Create+the+Next+One/26862984.html Tue, 04 Aug 2026 09:05:00 -0400 ABBV ABBV ANIK ANIK CNXU CNXU INMD INMD JNJ JNJ http://www.streetinsider.com/Press+Releases/Every+Few+Decades%2C+Aesthetics+Gets+a+New+Category.+One+Preclinical+Company+Thinks+Its+Extra+Cellular+Matrix+Platform+Could+Create+the+Next+One/26862984.html <p><strong>Issued on behalf of Conexeu Sciences Inc. (Nasdaq: CNXU)</strong></p><p>NEW YORK, Aug. 04, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=LrF4u_nq-M6rhKWRIFzyXu_SqHTmlF2LhuF9syLwk8f08DOVrOInZfGu4xhPcOF3GuPEXiVog2j84gNMhsUSgzuPzAL58AtKcaJ1ABt3xUc=" rel="nofollow" target="_blank">American News Group</a> <strong>News Commentary</strong> - The multi-billion-dollar medical aesthetics market is built on a handful of category-defining breakthroughs. The neuromodulator category that Botox^® created. The hyaluronic-acid filler category. The biostimulator category. Each turned a novel way of treating the face into a franchise measured in billions, and the companies that own those categories, from AbbVie (NYSE: ABBV) and Johnson &amp; Johnson (NYSE: JNJ) to InMode (Nasdaq: INMD) and Anika Therapeutics (Nasdaq: ANIK), built enormous businesses around them. Now http://www.streetinsider.com/Press+Releases/Every+Few+Decades%2C+Aesthetics+Gets+a+New+Category.+One+Preclinical+Company+Thinks+Its+Extra+Cellular+Matrix+Platform+Could+Create+the+Next+One/26862984.html Tue, 04 Aug 2026 09:05:00 -0400 ABBV ABBV ANIK ANIK CNXU CNXU INMD INMD JNJ JNJ http://www.streetinsider.com/Press+Releases/Every+Few+Decades%2C+Aesthetics+Gets+a+New+Category.+One+Preclinical+Company+Thinks+Its+Extra+Cellular+Matrix+Platform+Could+Create+the+Next+One/26862984.html <p><strong>Issued on behalf of Conexeu Sciences Inc. (Nasdaq: CNXU)</strong></p><p>NEW YORK, Aug. 04, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=LrF4u_nq-M6rhKWRIFzyXu_SqHTmlF2LhuF9syLwk8f08DOVrOInZfGu4xhPcOF3GuPEXiVog2j84gNMhsUSgzuPzAL58AtKcaJ1ABt3xUc=" rel="nofollow" target="_blank">American News Group</a> <strong>News Commentary</strong> - The multi-billion-dollar medical aesthetics market is built on a handful of category-defining breakthroughs. The neuromodulator category that Botox^® created. The hyaluronic-acid filler category. The biostimulator category. Each turned a novel way of treating the face into a franchise measured in billions, and the companies that own those categories, from AbbVie (NYSE: ABBV) and Johnson &amp; Johnson (NYSE: JNJ) to InMode (Nasdaq: INMD) and Anika Therapeutics (Nasdaq: ANIK), built enormous businesses around them. Now http://www.streetinsider.com/Press+Releases/Every+Few+Decades%2C+Aesthetics+Gets+a+New+Category.+One+Preclinical+Company+Thinks+Its+Extra+Cellular+Matrix+Platform+Could+Create+the+Next+One/26862984.html Tue, 04 Aug 2026 09:05:00 -0400 ABBV ABBV ANIK ANIK CNXU CNXU INMD INMD JNJ JNJ http://www.streetinsider.com/Press+Releases/Every+Few+Decades%2C+Aesthetics+Gets+a+New+Category.+One+Preclinical+Company+Thinks+Its+Extra+Cellular+Matrix+Platform+Could+Create+the+Next+One/26862984.html <p><strong>Issued on behalf of Conexeu Sciences Inc. (Nasdaq: CNXU)</strong></p><p>NEW YORK, Aug. 04, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=LrF4u_nq-M6rhKWRIFzyXu_SqHTmlF2LhuF9syLwk8f08DOVrOInZfGu4xhPcOF3GuPEXiVog2j84gNMhsUSgzuPzAL58AtKcaJ1ABt3xUc=" rel="nofollow" target="_blank">American News Group</a> <strong>News Commentary</strong> - The multi-billion-dollar medical aesthetics market is built on a handful of category-defining breakthroughs. The neuromodulator category that Botox^® created. The hyaluronic-acid filler category. The biostimulator category. Each turned a novel way of treating the face into a franchise measured in billions, and the companies that own those categories, from AbbVie (NYSE: ABBV) and Johnson &amp; Johnson (NYSE: JNJ) to InMode (Nasdaq: INMD) and Anika Therapeutics (Nasdaq: ANIK), built enormous businesses around them. Now http://www.streetinsider.com/Press+Releases/Every+Few+Decades%2C+Aesthetics+Gets+a+New+Category.+One+Preclinical+Company+Thinks+Its+Extra+Cellular+Matrix+Platform+Could+Create+the+Next+One/26862984.html Tue, 04 Aug 2026 09:05:00 -0400 ABBV ABBV ANIK ANIK CNXU CNXU INMD INMD JNJ JNJ http://www.streetinsider.com/Globe+Newswire/Every+Few+Decades%2C+Aesthetics+Gets+a+New+Category.+One+Preclinical+Company+Thinks+Its+Extra+Cellular+Matrix+Platform+Could+Create+the+Next+One/26862984.html <p><strong>Issued on behalf of Conexeu Sciences Inc. (Nasdaq: CNXU)</strong></p><p>NEW YORK, Aug. 04, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=LrF4u_nq-M6rhKWRIFzyXu_SqHTmlF2LhuF9syLwk8f08DOVrOInZfGu4xhPcOF3GuPEXiVog2j84gNMhsUSgzuPzAL58AtKcaJ1ABt3xUc=" rel="nofollow" target="_blank">American News Group</a> <strong>News Commentary</strong> - The multi-billion-dollar medical aesthetics market is built on a handful of category-defining breakthroughs. The neuromodulator category that Botox^® created. The hyaluronic-acid filler category. The biostimulator category. Each turned a novel way of treating the face into a franchise measured in billions, and the companies that own those categories, from AbbVie (NYSE: ABBV) and Johnson &amp; Johnson (NYSE: JNJ) to InMode (Nasdaq: INMD) and Anika Therapeutics (Nasdaq: ANIK), built enormous businesses around them. Now http://www.streetinsider.com/Globe+Newswire/Every+Few+Decades%2C+Aesthetics+Gets+a+New+Category.+One+Preclinical+Company+Thinks+Its+Extra+Cellular+Matrix+Platform+Could+Create+the+Next+One/26862984.html Tue, 04 Aug 2026 09:05:00 -0400 ABBV ABBV ANIK ANIK CNXU CNXU INMD INMD JNJ JNJ http://www.streetinsider.com/Globe+Newswire/Every+Few+Decades%2C+Aesthetics+Gets+a+New+Category.+One+Preclinical+Company+Thinks+Its+Extra+Cellular+Matrix+Platform+Could+Create+the+Next+One/26862984.html <p><strong>Issued on behalf of Conexeu Sciences Inc. (Nasdaq: CNXU)</strong></p><p>NEW YORK, Aug. 04, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=LrF4u_nq-M6rhKWRIFzyXu_SqHTmlF2LhuF9syLwk8f08DOVrOInZfGu4xhPcOF3GuPEXiVog2j84gNMhsUSgzuPzAL58AtKcaJ1ABt3xUc=" rel="nofollow" target="_blank">American News Group</a> <strong>News Commentary</strong> - The multi-billion-dollar medical aesthetics market is built on a handful of category-defining breakthroughs. The neuromodulator category that Botox^® created. The hyaluronic-acid filler category. The biostimulator category. Each turned a novel way of treating the face into a franchise measured in billions, and the companies that own those categories, from AbbVie (NYSE: ABBV) and Johnson &amp; Johnson (NYSE: JNJ) to InMode (Nasdaq: INMD) and Anika Therapeutics (Nasdaq: ANIK), built enormous businesses around them. Now http://www.streetinsider.com/Globe+Newswire/Every+Few+Decades%2C+Aesthetics+Gets+a+New+Category.+One+Preclinical+Company+Thinks+Its+Extra+Cellular+Matrix+Platform+Could+Create+the+Next+One/26862984.html Tue, 04 Aug 2026 09:05:00 -0400 ABBV ABBV ANIK ANIK CNXU CNXU INMD INMD JNJ JNJ http://www.streetinsider.com/Globe+Newswire/Every+Few+Decades%2C+Aesthetics+Gets+a+New+Category.+One+Preclinical+Company+Thinks+Its+Extra+Cellular+Matrix+Platform+Could+Create+the+Next+One/26862984.html <p><strong>Issued on behalf of Conexeu Sciences Inc. (Nasdaq: CNXU)</strong></p><p>NEW YORK, Aug. 04, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=LrF4u_nq-M6rhKWRIFzyXu_SqHTmlF2LhuF9syLwk8f08DOVrOInZfGu4xhPcOF3GuPEXiVog2j84gNMhsUSgzuPzAL58AtKcaJ1ABt3xUc=" rel="nofollow" target="_blank">American News Group</a> <strong>News Commentary</strong> - The multi-billion-dollar medical aesthetics market is built on a handful of category-defining breakthroughs. The neuromodulator category that Botox^® created. The hyaluronic-acid filler category. The biostimulator category. Each turned a novel way of treating the face into a franchise measured in billions, and the companies that own those categories, from AbbVie (NYSE: ABBV) and Johnson &amp; Johnson (NYSE: JNJ) to InMode (Nasdaq: INMD) and Anika Therapeutics (Nasdaq: ANIK), built enormous businesses around them. Now http://www.streetinsider.com/Globe+Newswire/Every+Few+Decades%2C+Aesthetics+Gets+a+New+Category.+One+Preclinical+Company+Thinks+Its+Extra+Cellular+Matrix+Platform+Could+Create+the+Next+One/26862984.html Tue, 04 Aug 2026 09:05:00 -0400 ABBV ABBV ANIK ANIK CNXU CNXU INMD INMD JNJ JNJ http://www.streetinsider.com/Globe+Newswire/Every+Few+Decades%2C+Aesthetics+Gets+a+New+Category.+One+Preclinical+Company+Thinks+Its+Extra+Cellular+Matrix+Platform+Could+Create+the+Next+One/26862984.html <p><strong>Issued on behalf of Conexeu Sciences Inc. (Nasdaq: CNXU)</strong></p><p>NEW YORK, Aug. 04, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=LrF4u_nq-M6rhKWRIFzyXu_SqHTmlF2LhuF9syLwk8f08DOVrOInZfGu4xhPcOF3GuPEXiVog2j84gNMhsUSgzuPzAL58AtKcaJ1ABt3xUc=" rel="nofollow" target="_blank">American News Group</a> <strong>News Commentary</strong> - The multi-billion-dollar medical aesthetics market is built on a handful of category-defining breakthroughs. The neuromodulator category that Botox^® created. The hyaluronic-acid filler category. The biostimulator category. Each turned a novel way of treating the face into a franchise measured in billions, and the companies that own those categories, from AbbVie (NYSE: ABBV) and Johnson &amp; Johnson (NYSE: JNJ) to InMode (Nasdaq: INMD) and Anika Therapeutics (Nasdaq: ANIK), built enormous businesses around them. Now http://www.streetinsider.com/Globe+Newswire/Every+Few+Decades%2C+Aesthetics+Gets+a+New+Category.+One+Preclinical+Company+Thinks+Its+Extra+Cellular+Matrix+Platform+Could+Create+the+Next+One/26862984.html Tue, 04 Aug 2026 09:05:00 -0400 ABBV ABBV ANIK ANIK CNXU CNXU INMD INMD JNJ JNJ http://www.streetinsider.com/Globe+Newswire/Every+Few+Decades%2C+Aesthetics+Gets+a+New+Category.+One+Preclinical+Company+Thinks+Its+Extra+Cellular+Matrix+Platform+Could+Create+the+Next+One/26862984.html <p><strong>Issued on behalf of Conexeu Sciences Inc. (Nasdaq: CNXU)</strong></p><p>NEW YORK, Aug. 04, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=LrF4u_nq-M6rhKWRIFzyXu_SqHTmlF2LhuF9syLwk8f08DOVrOInZfGu4xhPcOF3GuPEXiVog2j84gNMhsUSgzuPzAL58AtKcaJ1ABt3xUc=" rel="nofollow" target="_blank">American News Group</a> <strong>News Commentary</strong> - The multi-billion-dollar medical aesthetics market is built on a handful of category-defining breakthroughs. The neuromodulator category that Botox^® created. The hyaluronic-acid filler category. The biostimulator category. Each turned a novel way of treating the face into a franchise measured in billions, and the companies that own those categories, from AbbVie (NYSE: ABBV) and Johnson &amp; Johnson (NYSE: JNJ) to InMode (Nasdaq: INMD) and Anika Therapeutics (Nasdaq: ANIK), built enormous businesses around them. Now http://www.streetinsider.com/Globe+Newswire/Every+Few+Decades%2C+Aesthetics+Gets+a+New+Category.+One+Preclinical+Company+Thinks+Its+Extra+Cellular+Matrix+Platform+Could+Create+the+Next+One/26862984.html Tue, 04 Aug 2026 09:05:00 -0400 ABBV ABBV ANIK ANIK CNXU CNXU INMD INMD JNJ JNJ http://www.streetinsider.com/Globe+Newswire/Every+Few+Decades%2C+Aesthetics+Gets+a+New+Category.+One+Preclinical+Company+Thinks+Its+Extra+Cellular+Matrix+Platform+Could+Create+the+Next+One/26862984.html <p><strong>Issued on behalf of Conexeu Sciences Inc. (Nasdaq: CNXU)</strong></p><p>NEW YORK, Aug. 04, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=LrF4u_nq-M6rhKWRIFzyXu_SqHTmlF2LhuF9syLwk8f08DOVrOInZfGu4xhPcOF3GuPEXiVog2j84gNMhsUSgzuPzAL58AtKcaJ1ABt3xUc=" rel="nofollow" target="_blank">American News Group</a> <strong>News Commentary</strong> - The multi-billion-dollar medical aesthetics market is built on a handful of category-defining breakthroughs. The neuromodulator category that Botox^® created. The hyaluronic-acid filler category. The biostimulator category. Each turned a novel way of treating the face into a franchise measured in billions, and the companies that own those categories, from AbbVie (NYSE: ABBV) and Johnson &amp; Johnson (NYSE: JNJ) to InMode (Nasdaq: INMD) and Anika Therapeutics (Nasdaq: ANIK), built enormous businesses around them. Now http://www.streetinsider.com/Globe+Newswire/Every+Few+Decades%2C+Aesthetics+Gets+a+New+Category.+One+Preclinical+Company+Thinks+Its+Extra+Cellular+Matrix+Platform+Could+Create+the+Next+One/26862984.html Tue, 04 Aug 2026 09:05:00 -0400 ABBV ABBV ANIK ANIK CNXU CNXU INMD INMD JNJ JNJ http://www.streetinsider.com/Globe+Newswire/Every+Few+Decades%2C+Aesthetics+Gets+a+New+Category.+One+Preclinical+Company+Thinks+Its+Extra+Cellular+Matrix+Platform+Could+Create+the+Next+One/26862984.html <p><strong>Issued on behalf of Conexeu Sciences Inc. (Nasdaq: CNXU)</strong></p><p>NEW YORK, Aug. 04, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=LrF4u_nq-M6rhKWRIFzyXu_SqHTmlF2LhuF9syLwk8f08DOVrOInZfGu4xhPcOF3GuPEXiVog2j84gNMhsUSgzuPzAL58AtKcaJ1ABt3xUc=" rel="nofollow" target="_blank">American News Group</a> <strong>News Commentary</strong> - The multi-billion-dollar medical aesthetics market is built on a handful of category-defining breakthroughs. The neuromodulator category that Botox^® created. The hyaluronic-acid filler category. The biostimulator category. Each turned a novel way of treating the face into a franchise measured in billions, and the companies that own those categories, from AbbVie (NYSE: ABBV) and Johnson &amp; Johnson (NYSE: JNJ) to InMode (Nasdaq: INMD) and Anika Therapeutics (Nasdaq: ANIK), built enormous businesses around them. Now http://www.streetinsider.com/Globe+Newswire/Every+Few+Decades%2C+Aesthetics+Gets+a+New+Category.+One+Preclinical+Company+Thinks+Its+Extra+Cellular+Matrix+Platform+Could+Create+the+Next+One/26862984.html Tue, 04 Aug 2026 09:05:00 -0400 ABBV ABBV ANIK ANIK CNXU CNXU INMD INMD JNJ JNJ http://www.streetinsider.com/Globe+Newswire/Every+Few+Decades%2C+Aesthetics+Gets+a+New+Category.+One+Preclinical+Company+Thinks+Its+Extra+Cellular+Matrix+Platform+Could+Create+the+Next+One/26862984.html <p><strong>Issued on behalf of Conexeu Sciences Inc. (Nasdaq: CNXU)</strong></p><p>NEW YORK, Aug. 04, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=LrF4u_nq-M6rhKWRIFzyXu_SqHTmlF2LhuF9syLwk8f08DOVrOInZfGu4xhPcOF3GuPEXiVog2j84gNMhsUSgzuPzAL58AtKcaJ1ABt3xUc=" rel="nofollow" target="_blank">American News Group</a> <strong>News Commentary</strong> - The multi-billion-dollar medical aesthetics market is built on a handful of category-defining breakthroughs. The neuromodulator category that Botox^® created. The hyaluronic-acid filler category. The biostimulator category. Each turned a novel way of treating the face into a franchise measured in billions, and the companies that own those categories, from AbbVie (NYSE: ABBV) and Johnson &amp; Johnson (NYSE: JNJ) to InMode (Nasdaq: INMD) and Anika Therapeutics (Nasdaq: ANIK), built enormous businesses around them. Now http://www.streetinsider.com/Globe+Newswire/Every+Few+Decades%2C+Aesthetics+Gets+a+New+Category.+One+Preclinical+Company+Thinks+Its+Extra+Cellular+Matrix+Platform+Could+Create+the+Next+One/26862984.html Tue, 04 Aug 2026 09:05:00 -0400 ABBV ABBV ANIK ANIK CNXU CNXU INMD INMD JNJ JNJ http://www.streetinsider.com/Globe+Newswire/Every+Few+Decades%2C+Aesthetics+Gets+a+New+Category.+One+Preclinical+Company+Thinks+Its+Extra+Cellular+Matrix+Platform+Could+Create+the+Next+One/26862984.html <p><strong>Issued on behalf of Conexeu Sciences Inc. (Nasdaq: CNXU)</strong></p><p>NEW YORK, Aug. 04, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=LrF4u_nq-M6rhKWRIFzyXu_SqHTmlF2LhuF9syLwk8f08DOVrOInZfGu4xhPcOF3GuPEXiVog2j84gNMhsUSgzuPzAL58AtKcaJ1ABt3xUc=" rel="nofollow" target="_blank">American News Group</a> <strong>News Commentary</strong> - The multi-billion-dollar medical aesthetics market is built on a handful of category-defining breakthroughs. The neuromodulator category that Botox^® created. The hyaluronic-acid filler category. The biostimulator category. Each turned a novel way of treating the face into a franchise measured in billions, and the companies that own those categories, from AbbVie (NYSE: ABBV) and Johnson &amp; Johnson (NYSE: JNJ) to InMode (Nasdaq: INMD) and Anika Therapeutics (Nasdaq: ANIK), built enormous businesses around them. Now http://www.streetinsider.com/Globe+Newswire/Every+Few+Decades%2C+Aesthetics+Gets+a+New+Category.+One+Preclinical+Company+Thinks+Its+Extra+Cellular+Matrix+Platform+Could+Create+the+Next+One/26862984.html Tue, 04 Aug 2026 09:05:00 -0400 ABBV ABBV ANIK ANIK CNXU CNXU INMD INMD JNJ JNJ